FGF-23 removal is improved by on-line high-efficiency hemodiafiltration compared to conventional high flux hemodialysis

Journal of Nephrology

Volumn 26, Issue 2, 2013, Pages 342-349

  Patrier, Laure ^a,b   Dupuy, Anne Marie ^a   Granger Vallée, Alexandre ^a   Chalabi, Lotfi ^c   Morena, Marion ^a,b   Canaud, Bernard ^a,b,c   Cristol, Jean Paul ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b University Montpellier 1 et 2   (France)

^c Jacques Mirouze Clinic   (France)

Author keywords

FGF 23; FGF23; Hemodiafiltration; Hemodialysis

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; UREA;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMPARATIVE EFFECTIVENESS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIAFILTRATION; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; KIDNEY CLEARANCE; KIDNEY PLASMA FLOW; MAJOR CLINICAL STUDY; MALE; ON LINE HEMODIAFILTRATION; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; UREA BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EQUIPMENT DESIGN; FEMALE; FIBROBLAST GROWTH FACTORS; HEMODIAFILTRATION; HUMANS; LINEAR MODELS; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; POLYMERS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SULFONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877320094     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000150     Document Type: Article

References (35)

1. Fukagawa M, Nii-Kono T, Kazama JJ. Role of fibroblast growth factor 23 in health and in chronic kidney disease. Curr Opin Nephrol Hypertens. 2005;14(4):325-329.
2. Nishi H, Nii-Kono T, Nakanishi S, et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract. 2005;101(2):c94-99.
3. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF-23: regulation by phosphate? Bone. 2004; 35(5):1192-1199.
4. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem. 2003;278(4):2206-2211.
5. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429-435.
6. Shigematsu T, Kazama JJ, Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004;44(2):250-256.
7. Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 2005;67(3): 1171-1178.
8. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2010;77(3):211-218.
9. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205-2215.
10. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64(6):2272-2279.
11. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584-592.
12. Jean G, Bresson E, Terrat JC, et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant. 2009;24(3):948-955.
13. Coen G, De Paolis P, Ballanti P, et al. Peripheral artery calcifications evaluated by histology correlate to those detected by CT: relationships with fetuin-A and FGF-23. J Nephrol. 2011;24(3):313-321.
14. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant. 2010;25(8): 2679-2685.
15. Kanbay M, Nicoleta M, Selcoki Y, et al. Fibroblast Growth Factor 23 and Fetuin A are Independent Predictors for the Coronary Artery Disease Extent in Mild Chronic Kidney Disease. Clin J Am Soc Nephrol. 2010;5(10):1780-1786.
16. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011 15; 305(23): 2432-2439.
17. Torres PU, Friedlander G, De Vernejoul MC, Silve C, Prié D. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int. 2008; 73:102-107.
18. Lin CL, Yang CW, Chiang CC, Chang CT, Huang CC. Longterm on-line hemodiafiltration reduces predialysis beta-2-microglobulin levels in chronic hemodialysis patients. Blood Purif. 2001;19(3):301-307.
19. Locatelli F, Manzoni C, Del Vecchio L, Cavalli A, Pontoriero G. Recent trials on hemodiafiltration. Contrib Nephrol. 2011; 171:92-100.
20. Badiou S, Dupuy AM, Descomps B, Cristol JP. Comparison between the enzymatic vitros assay for creatinine determination and three other methods adapted on the Olympus analyzer. J Clin Lab Anal. 2003;17(6):235-240.
21. Bergström J, Wehle B. No change in corrected beta 2-microglobulin concentration after cuprophane haemodialysis. Lancet. 1987;1(8533):628-629.
22. Cheung AK, Rocco MV, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol. 2006;17(2):546-555.
23. Marsell R, Grundberg E, Krajisnik T, et al. Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. Eur J Endocrinol. 2008;158(1):125-129.
24. Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 2004;65(5):1943-1946.
25. Krieter DH, Hunn E, Morgenroth A, Lemke HD, Wanner C. Matching efficacy of on-line hemodiafiltration in simple hemodialysis mode. Artif Organs. 2008;32(12):903-909.
26. Maduell F, Sánchez-Canel JJ, Blasco JA, et al. [Middle molecules removal. Beyond beta2-microglobulin]. Nefrologia. 2006;26(4):469-475.
27. Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol. 2007;194(1):1-10.
28. Kato K, Jeanneau C, Tarp MA, et al. Polypeptide GalNActransferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem. 2006;281(27):18370-18377.
29. Ichikawa S, Sorenson AH, Austin AM, et al. Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. Endocrinology. 2009; 150(6):2543-2550.
30. Ichikawa S, Imel EA, Sorenson AH, et al. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. J Clin Endocrinol Metab. 2006;91(11):4472-4475.
31. Garringer HJ, Fisher C, Larsson TE, et al. The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N--acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab. 2006;91(10):4037-4042.
32. Benet-Pagès A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF-23 missense mutation causes familial tumoral calcino sis with hyperphosphatemia. Hum Mol Genet. 2005;14(3): 385-390.
33. Goetz R, Nakada Y, Hu MC, et al. Isolated C-terminal tail of FGF-23 alleviates hypophosphatemia by inhibiting FGF-23--FGFR-Klotho complex formation. Proc Natl Acad Sci U S A. 2010;107(1):407-412.
34. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393-4408.
35. Khosravi A, Cutler CM, Kelly MH, et al. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab. 2007;92(6):2374-2377.